Immune-based strategies for mood disorders: facts and challenges

Gabriela D. Colpo, Marion Leboyer, Robert Dantzer, Mahdukar H. Trivedi, Antonio L. Teixeira

Producción científica: Review articlerevisión exhaustiva

71 Citas (Scopus)


Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.

Idioma originalEnglish (US)
Páginas (desde-hasta)139-152
Número de páginas14
PublicaciónExpert Review of Neurotherapeutics
EstadoPublished - feb 1 2018
Publicado de forma externa

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology
  • Pharmacology (medical)


Profundice en los temas de investigación de 'Immune-based strategies for mood disorders: facts and challenges'. En conjunto forman una huella única.

Citar esto